Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 153-162

  Loibl, Sibylle ^a,i   Volz, Cristina ^b   Mau, Christine ^b   Blohmer, Jens Uwe ^c   Costa, Serban D ^d   Eidtmann, Holger ^e   Fasching, Peter A ^f   Gerber, Bernd ^g   Hanusch, Claus ^h   Jackisch, Christian ⁱ   Kümmel, Sherko ^j   Huober, Jens ^k   Denkert, Carsten ^l   Hilfrich, Jörn ^m   Konecny, Gottfried E ⁿ   Fett, Werner ^o   Stickeler, Elmar ^p   Harbeck, Nadia ^q   Mehta, Keyur M ^a   Nekljudova, Valentina ^a   Von Minckwitz, Gunter ^a,r   Untch, Michael ^b   more..

^a GBG Forschungs GmbH   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g KLINIKUM NÜRNBERG   (Germany)

^h Rotkreuzklinikum   (Germany)

ⁱ SANA KLINIKUM OFFENBACH   (Germany)

^j KLINIKEN ESSEN MITTE   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m Department of Obstetrics and Gynecology Eilenriedklinik ^*  (Germany)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o Hematologic/Oncologic Practice   (Germany)

^p UNIVERSITY OF FREIBURG   (Germany)

^q UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Breast cancer; Invasive lobular carcinoma; Neoadjuvant chemotherapy; Non lobular carcinoma; Pathological complete response; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84896712889     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2861-6     Document Type: Article

References (38)

1. Li CI, Anderson BO, Daling JR et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421-1424
2. Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumour characteristics and clinical outcome. Breast Cancer Res 6(3):R149-R156
3. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
4. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046-1052
5. Rakha EA, Ellis IO (2010) Lobular breast carcinoma and its variants. Semin Diagn Pathol 27(1):49-61
6. Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113(7):1511-1520
7. Reis-Filho JS, Simpson PT, Jones C et al (2005) Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207(1):1-13
8. Lips EH, Mulder L, de Ronde JJ et al (2012) Neoadjuvant chemotherapy in ER+ HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 131(3):827-836
9. von Minckwitz G, Untch M, Blohmer J-U et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804
10. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41-48
11. von Minckwitz G, Costa SD, Raab G et al (2001) Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 19(15):3506-3515
12. Untch M, Loibl S, Bischoff J et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13(2):135-144
13. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
14. Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351-3357
15. von Minckwitz G, Rezai M, Loibl S et al (2010) Capecitabine in addition to anthracycline/taxane-based neoadjuvant treatment in patients with primary breast cancer: the phase III GeparQuattro study. J Clin Oncol 28(12):2015-2023
16. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366(4):299-309
17. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12):2676-2685
18. Thomssen C, Scharl A, Harbeck N (2011) AGO recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer. Update 2011. Breast Care (Basel) 6(4):299-313
19. Purushotham A, Pinder S, Cariati M et al (2010) Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 28(22):3552-3554
20. Katz A, Saad ED, Porter P et al (2007) Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8(1):55-62
21. Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlight of the St. Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 24(9):2206-2223
22. Boughey JC, Wagner J, Garrett BJ et al (2009) Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Annals Surg Oncol 16(6):1606-1611
23. Delpech Y, Coutant C, Hsu L et al (2013) Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108(2):285-291
24. Morrow M, Kiney K, Scholtens D et al (2006) Selecting patients for breast conserving surgery - The Importance of Lobular Histology. Cancer 106(12):2563-2568
25. Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19(6):1688-1697
26. Diepenmaat LA, van der Sangen M, van de Poll-Franse LV et al (2009) The impact of postmastectomy radiotherapy on local control in patients with invasive lobular breast cancer. Radiother Oncol 91(1):49-53
27. Biglia N, Maggiorotto F, Liberale V et al (2013) Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol 39(5):455-460
28. Vo T, Meric-Bernstam F, Yi Min et al (2006) Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192(4):552-555
29. Colleoni M, Rotmensz N, Maisonneuve P et al (2012) Outcome of special types of luminal breast cancer. Ann Oncol 23(6):1428-1436
30. Cortazar P, Zhang L, Untch M et al (2012) Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res 72(24 Suppl.):S1-S11
31. Noske A, Loibl S, Darb-Esfahani S et al (2011) Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 126(1):109-117
32. Denkert C, Huober J, Loibl S et al (2013) HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 15:R11
33. Metzger-Filho O, Procter M, de Azambuja E et al (2013) Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol 31(16):1954-1960
34. Longacre TA, Ennis M, Quenneville LA et al (2006) Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19(2):195-207
35. Kiaer H, Andersen JA, Rank F et al (1988) Quality control of patho-anatomical diagnosis of carcinoma of the breast. Acta Oncol 27(6A):745-747
36. Rakha EA, El-Sayed ME, Menon S et al (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111(1):121-127
37. Metzger-Filho O, Michiels S, Bertucci F et al (2013) Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol 24(2):377-384
38. Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44:73-83